ABSTRACT

Introduction

The therapeutic landscape for psoriasis is ever-changing. Risankizumab is the newest approved biologic and one of three currently licensed that targets the p19 subunit of interleukin-23 (IL-23). It is increasingly clear that different biologics vary in their efficacy, effectiveness, and safety profiles, highlighting that there is a need to understand for which patients and in which circumstances to use each drug.

Areas covered

This article summarizes original clinical trial data, and reviews in more detail recent post-marketing studies and meta-analyses that differentiate risankizumab from other biologics. It also briefly explores the evidence for risankizumab in the treatment of other immune-mediated inflammatory diseases.

Expert opinion

Risankizumab is a highly effective biologic for the treatment of moderate-to-severe plaque psoriasis. Recent open-label extension data for risankizumab shows sustained treatment responses to week 136. Indirect comparisons suggest IL-17 inhibitors have a faster onset, though head-to-head comparison with secukinumab shows non-inferiority at week 16 and superiority of risankizumab at week 52. Risankizumab is very well tolerated and data from the IMMhance trial suggests that risankizumab can be used in patients with latent tuberculosis without risk of reactivation.

中文翻译：

---

risankizumab 治疗中度至重度银屑病的最新进展。

摘要

介绍

牛皮癣的治疗前景是不断变化的。Risankizumab 是最新获批的生物制剂，也是目前获得许可的三种靶向白细胞介素 23 (IL-23) p19 亚基的生物制剂之一。越来越清楚的是，不同的生物制剂在疗效、有效性和安全性方面存在差异，这突出表明有必要了解每种药物适用于哪些患者以及在何种情况下使用。

涵盖的领域

本文总结了原始临床试验数据，并更详细地回顾了近期上市后研究和荟萃分析，这些研究将 risankizumab 与其他生物制剂区分开来。它还简要探讨了 risankizumab 在治疗其他免疫介导的炎症性疾病中的证据。

专家意见

Risankizumab 是一种用于治疗中度至重度斑块型银屑病的高效生物制剂。最近 risankizumab 的开放标签扩展数据显示第 136 周的治疗反应持续。间接比较表明 IL-17 抑制剂起效更快，尽管与 secukinumab 的头对头比较显示第 16 周的非劣效性和 risankizumab 在一周的优势52. Risankizumab 的耐受性非常好，来自 IMMhance 试验的数据表明，risankizumab 可用于潜伏性结核病患者而没有再激活的风险。